[go: up one dir, main page]

Eckardt, 2008 - Google Patents

Therapeutic Options in the Treatment of Diabetes

Eckardt, 2008

View PDF
Document ID
5981506456818481220
Author
Eckardt K
Publication year

External Links

Snippet

The induction of insulin resistance in peripheral organs like skeletal muscle is an early defect in the pathogenesis of type 2 diabetes. It has been known for some years that obesity and insulin resistance are closely associated and that adiposity is a high risk factor for the …
Continue reading at docserv.uni-duesseldorf.de (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N-C(=NH)-NH2), isourea (N=C(OH)-NH2), isothiourea (-N=C(SH)-NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (-N=N-), diazo (=N2), azoxy (>N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application

Similar Documents

Publication Publication Date Title
Potenza et al. Vascular actions of insulin with implications for endothelial dysfunction
Fujii et al. AMP-activated protein kinase and the regulation of glucose transport
Bansal et al. Insulin as a physiological modulator of glucagon secretion
Plante et al. Oxytocin treatment prevents the cardiomyopathy observed in obese diabetic male db/db mice
Jiang et al. Glucagon and regulation of glucose metabolism
Hattori et al. RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells
Di Marzo CB1 receptor antagonism: biological basis for metabolic effects
JP6338531B2 (en) Tetrahydrocannabinalin (THCV) for use in the protection of islet cells
Turner et al. Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities
Chen et al. Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice
Khan et al. Current updates in the medical management of obesity
Hua et al. Beta-klotho in type 2 diabetes mellitus: from pathophysiology to therapeutic strategies
EP3104873B1 (en) Fgf-8 for use in treating diseases or disorders of energy homeostasis
Bailey Future drug treatments for type 2 diabetes
Akasaka et al. Direct evidence for leptin-induced lipid oxidation independent of long-form leptin receptor
Isshiki et al. Insulin regulates SOCS2 expression and the mitogenic effect of IGF-1 in mesangial cells
Eckardt Therapeutic Options in the Treatment of Diabetes
S Sahajpal et al. Molecular remodeling of the insulin receptor pathway by thiazolidinediones in type 2 diabetes mellitus: A brief review
Kautzky-Willer et al. Obesity and diabetes
Meerza et al. Pharmacology of signaling pathways: In type 2 diabetes
Auge Intracellular events in diabetes mellitus–Behind the scenes.
Lin et al. The Endocrine Actions of Undercarboxylated Osteocalcin in Skeletal Muscle: Effects and Mechanisms
Sattar et al. Globular adiponectin activates Akt in cultured myocytes
Toor et al. Molecular Mechanisms of Diabetes Mellitus
US20150037361A1 (en) Compositions and methods to treat the bihormonal disorder in diabetes